ArticleEuropean journal of nuclear medicine and molecular imaging2026
Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal [18 F]FDG-PET/CT criteria for assessing metabolic response to immunotherapy in melanoma remain debated. This study aimed to compare the prognostic performance of PECRIT, PERCIMT, and EORTC criteria in a cohort of advanced melanoma patients.
methodsWe retrospectively evaluated patients with advanced melanoma undergoing immune checkpoint inhibitors (ICIs) therapy who underwent baseline and interim [18 F]FDG-PET/CT scans. A per-patient metabolic response was categorized as Complete (CMR), Partial (PMR), Stable (SMD), or Progressive Metabolic Disease (PMD) using PECRIT, PERCIMT, and EORTC criteria. Baseline tumor burden was assessed by lesion count and volumetric parameters (MTV, TLG) were explored. Response agreement between criteria was evaluated, and survival analysis (Overall Survival, OS, and Progression-Free Survival, PFS) was performed using Kaplan-Meier and Log-rank tests. Patients were further dichotomized into Disease Control Group (DCG: CMR + PMR+SMD) versus No-DCG (PMD), and Objective Response Group (ORG: CMR + PMR) versus Non-ORG (SMD + PMD).
resultsA total of 46 patients were included. At a median follow-up of 29.1 months, 30/46 patients (65%) progressed and 22/46 (48%) died, with a median OS of 24.6 months (IQR 13.9-41.4) and a median PFS of 10.7 months (IQR 5.3-24.7) for the entire cohort. Specifically, discordance between criteria occurred in 16/46 (35%) cases, predominantly involving PECRIT/EORTC PMD versus PERCIMT SMD (8 cases, 50% of the discordant cases). Prognostic analysis revealed significant differences in PFS and OS between response groups across all three evaluated criteria. Patients in the DCG had significantly longer PFS across all criteria (all p ≤ 0.012), and patients in the ORG had s significantly longer OS for PECRIT (p = 0.039) and EORTC (p = 0.003).
conclusionAll three criteria provide valuable prognostic insights for survival in immunotherapy-treated melanoma. However, notable discordance exists in response classification, particularly regarding the definition of progressive disease. The dichotomized approach (DCG/ORG) appears to represent a promising, clinically relevant tool to consolidate metabolic response assessment, facilitating a more consistent prediction of patient outcomes in the clinical setting.
Indexed as
Identifiers
42595801What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.